The Centers for Medicare and Medicaid Services launched the GLP-1 Bridge Program on July 1 to assist qualifying Medicare beneficiaries with the cost of weight-loss medications. While the initiative provides a path for access to drugs like Wegovy at reduced rates, participants are encountering hurdles at the point of sale.
Rebecca McWilliams, a resident of York, Pennsylvania, recently qualified for the program. Despite official approval, she faced a denial at her local pharmacy. According to McWilliams, the pharmacy staff indicated they lacked the knowledge to process the claim under the new government pilot requirements.
A spokesperson for CVS confirmed the incident, citing an error with the patient’s Medicare beneficiary identifier as the primary reason for the rejection. The chain stated that the prescription would have been processed correctly if the information had been accurate.
Federal officials advise patients using the program to ensure their pharmacists are processing claims through the specific Medicare GLP-1 Bridge central billing system rather than the standard Part D route. Currently, approximately 250,000 Medicare-eligible individuals are part of this pilot program, which is subject to ongoing government evaluation.